New blood test detects liver cirrhosis risk early
Singaporean researchers have developed a non-invasive blood test called CIRRHOClear that uses microRNA biomarkers to detect liver cirrhosis risk. The test shows high accuracy in identifying patients before symptoms appear, potentially reducing liver failure and cancer rates.
Why it matters
Early detection of chronic liver conditions can significantly improve patient outcomes and reduce the burden on healthcare systems.
Mirxes co-founder and chief executive Zhou Lihan (left) with Pierce Chow, senior consultant in the division of surgery and surgical oncology at Singapore General Hospital and National Cancer Centre Singapore.
Listen Summarise Singapore researchers have developed CIRRHOClear, a blood test that uses microRNA biomarkers to spot liver cirrhosis risk before symptoms appear. Clinical studies found it identified cirrhosis in 89% of cases and ruled it out 95% of the time, helping doctors assess higher-risk people earlier. Doctors say early detection could prevent liver failure and liver cancer, while avoiding limits of current tests and reducing care bottlenecks. AI generated
SINGAPORE – A new blood test developed in Singapore can help to flag early the risk of a condition that can lead to liver failure and a common form of liver cancer.
Dubbed CIRRHOClear, the non-invasive test is designed to identify liver cirrhosis risk before symptoms appear.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in